Matthew Bogoyas
Psychiatry · Yakima, WANPI 1336508423
Payments from drug & device makers
Across 1,079 payments — averaging $463.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$155K
- E.r. Squibb & Sons, L.L.C.$109K
- Neurocrine Biosciences, Inc.$96K
- Otsuka America Pharmaceutical, Inc.$70K
- Axsome Therapeutics, Inc.$54K
- Janssen Scientific Affairs, LLC$9K
- plus $6K from 13 others
What the payments were for
- Consulting fees$66,37413%
- Speaking & faculty fees$372,84575%
- Travel & lodging$34,9847%
- Food & beverage$24,8695%
- Education$7620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 270 | $155,177 |
| E.r. Squibb & Sons, L.L.C. | 137 | $109,203 |
| Neurocrine Biosciences, Inc. | 144 | $96,022 |
| Otsuka America Pharmaceutical, Inc. | 187 | $70,006 |
| Axsome Therapeutics, Inc. | 81 | $54,293 |
| Janssen Scientific Affairs, LLC | 10 | $9,144 |
| Johnson & Johnson | 49 | $1,291 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 86 | $1,246 |
| Alkermes, Inc. | 38 | $1,219 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 10 | $631 |
| AbbVie(2 entities) | 18 | $479 |
| Indivior Inc. | 22 | $444 |
| Sunovion Pharmaceuticals Inc. | 13 | $370 |
| Supernus Pharmaceuticals, Inc. | 7 | $137 |
| Lundbeck LLC | 1 | $67 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $64 |
| Seqirus USA Inc | 1 | $15 |
| Eisai Inc. | 1 | $14 |
| Vanda Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$93,681
- UZEDY$82,883
- COBENFY$82,751
- ABILIFY MAINTENA$68,029
- Austedo XR$62,147
- Auvelity$52,823
- ABILIFY ASIMTUFII$42,159
- INVEGA SUSTENNA$8,676
- SPRAVATO$8,175
- AUSTEDO$6,531
- LYBALVI$1,440
- INVEGA TRINZA$1,028
- ARISTADA$890
- VRAYLAR$375
- REXULTI$334
- INVEGA$261
- RISPERDAL$261
- CAPLYTA$250
- ARISTADA INITIO$223
- LATUDA$125
How this compares
$499,834 in reported general payments places this provider in the 95th percentile of 576 psychiatry providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 140 | $460,203 |
| Austedo XrDeutetrabenazine | 31 | $303,719 |
| UzedyRisperidone | 63 | $225,867 |
| CaplytaLumateperone Tosylate | 78 | $128,652 |
| IngrezzaValbenazine Tosylate | 15 | $123,086 |
| Abilify MaintenaAripiprazole | 28 | $83,753 |
| RexultiBrexpiprazole | 26 | $39,432 |
| LybalviOlanzapine/Samidorphan Malate | 14 | $20,530 |
| Risperdal ConstaRisperidone Microspheres | 20 | $18,810 |
| QelbreeViloxazine Hcl | 18 | $18,083 |
| Varenicline Tartrate | 37 | $9,292 |
| Clozapine | 91 | $7,517 |
| Chlorpromazine Hcl | 16 | $7,242 |
| Divalproex Sodium ErDivalproex Sodium | 111 | $6,573 |
| Fluphenazine Hcl | 19 | $5,300 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Uzedy | $155,177 | $529,58694 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $1,291 | $479,013160 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,246 | $128,65278 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $70,006 | $123,18554 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $96,022 | $123,08615 claims |
| Alkermes, Inc.Lybalvi | $1,219 | $20,53014 claims |
| Supernus Pharmaceuticals, Inc.Qelbree | $137 | $18,08318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 576 psychiatry providers in Washington.
Other psychiatry in Yakima
- Frank GarnerYakima$2K
- Arifulla KhanBellevue$35.6M
- Arun AroraBellevue$10.6M
- Jeffrey HansenVancouver$2.8M
- Chester RobachinskiSeattle$1.1M
- Larry BornsteinEverett$663K
- David DunnerMercer Island$649K
- Aishwarya PrasadBellevue$323K
- Shirin SchillingEverett$263K
- Pablo ProanoSeattle$112K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.